Positive FDA Feedback to Progress Bexmarilimab
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Inside Information: Faron Announces Positive US Food and Drug Administration (FDA) Feedback to Progress Bexmarilimab as a Monotherapy in Solid Tumors Green light for continued clinical development after data package review Alignment with company’s selection of 1 mg/kg IV once-every-3-weeks (Q3W) as dose for further evaluation Supportive of biomarker-driven approach with CLEVER-1 staining of tumor biopsy Company announcement, March 22, 2023 at 03:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM (EET) Inside